Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00422799
Other study ID # 06-008
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date August 30, 2006
Est. completion date October 9, 2015

Study information

Verified date October 2020
Source Dana-Farber Cancer Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In this study, we are trying to find out if the combination of these two drugs is effective in treating Waldenstrom's macroglobulinemia (WM). The combination of these two drugs has not been studied for patients with relapsed or refractory macroglobulinemia. The U.S. Food and Drug Administration (FDA) has approved bortezomib for the treatment of multiple myeloma, a cancer that is closely related to Waldenstrom's macroglobulinemia.


Description:

- Participants will receive 6 cycles of the study treatment with bortezomib and rituximab. Each cycle is 28 days long (4 weeks). - Participants will receive Rituximab intravenously once a week for the first and fourth cycles only. Participants will receive bortezomib once a week for three weeks on and one week off every cycle, for a total of 6 cycles. - During the rituximab infusion, the participants blood pressure and pulse will be monitored frequently. The rate of infusion may be decreased depending upon the side effects that are experienced. - Blood samples will be collected before the first dose and on follow up with every cycle. Blood counts will also be performed every week. - Routine physical exams will be performed at each evaluation. A PET/CAT scan of the chest, abdomen and pelvis at the end of treatment. This scan is required to assess the response of the participants disease. - In order to learn more on how bortezomib and rituximab affect WM, a bone marrow biopsy will be performed. - We anticipate that participants will complete the active therapy over a period of 6 cycles provided that they are benefiting from therapy and have not had any serious side effects. The participant will be followed every three months for 2 years for office visits and laboratory tests.


Recruitment information / eligibility

Status Completed
Enrollment 63
Est. completion date October 9, 2015
Est. primary completion date October 9, 2015
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - 18 years of age or older - Patients with previously untreated WM and those who have received prior therapy are eligible - Must have received prior therapy for their WM and have relapsed or refractory WM. - CD20 positive disease based on any previous bone marrow immuno-histochemistry or flow cytometric analysis performed up to 3 months prior to enrollment. - Measurable disease - ECOG Performance Status 0,1, or 2 - Total bilirubin < 2.0 mg/dl - AST < 3 x ULN - Life expectancy of greater than 12 weeks Exclusion Criteria: - Uncontrolled infection - Other active malignancies - Cytotoxic chemotherapy less than 3 weeks, or biologic therapy less than 2 weeks, or corticosteroids less than 2 weeks, prior to registration. - Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational - Known to be HIV positive or HEP B positive - Radiation therapy less than 2 weeks prior to registration - Grade 2 or greater peripheral neuropathy - Myocardial infarction within 6 months rior to enrollment or has NYHA Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. - Hypersensitivity to bortezomib, boron, or mannitol - Pregnant or breast feeding women - Other investigational drugs within 14 days of enrollment - Serious medical or psychiatric illness likely to interfere with participation

Study Design


Intervention

Drug:
Bortezomib
Once weekly for 3 weeks
Rituximab
Intravenously once a week for the first and fourth weeks of a cycle

Locations

Country Name City State
United States Dana-Farber Cancer Institute Boston Massachusetts

Sponsors (2)

Lead Sponsor Collaborator
Dana-Farber Cancer Institute Millennium Pharmaceuticals, Inc.

Country where clinical trial is conducted

United States, 

References & Publications (1)

Ghobrial IM, Hong F, Padmanabhan S, Badros A, Rourke M, Leduc R, Chuma S, Kunsman J, Warren D, Harris B, Sam A, Anderson KC, Richardson PG, Treon SP, Weller E, Matous J. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or rela — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Overall Response Rate of Bortezomib and Rituximab (VR) in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia (WM) Overall Response Rate= Minor response (>25%-50% reduction in monoclonal IgM from baseline + Partial Response (>50-90% reduction in monoclonal IgM from baseline)+ Complete Response (Disappearance of monoclonal protein by immunofixation; no histologic evidence of bone marrow involvement, resolution of any adenopathy/organomegaly (confirmed by CT scan), or signs or symptoms attributable to WM. Reconfirmation of the CR status is required at least 6 weeks apart with a second immunofixation.) 2 Years
Primary Overall Response Rate of Bortezomib and Rituximab (VR) in Patients With Previously Untreated Waldenstrom's Macroglobulinemia (WM) Overall Response Rate= Minor response (>25%-50% reduction in monoclonal IgM from baseline + Partial Response (>50-90% reduction in monoclonal IgM from baseline)+ Complete Response (Disappearance of monoclonal protein by immunofixation; no histologic evidence of bone marrow involvement, resolution of any adenopathy/organomegaly (confirmed by CT scan), or signs or symptoms attributable to WM. Reconfirmation of the CR status is required at least 6 weeks apart with a second immunofixation.) 2 years
Secondary Time to Progression in Patients With WM Time to progresion is the defined as the time from study entry to disease progression (PD) or death. Patients without PD are censored at the date of last disease evaluation. PD is defined as a greater than 25% increase in serum monoclonal IgM electrophoresis confirmed by a second measurement at least 2 weeks apart, or progression of clinically significant findings due to disease or symptoms attributable to WM. 5 Years
Secondary Duration of Response in Patients With WM Time from documentation of first response to progressive disease. 5 Years
See also
  Status Clinical Trial Phase
Completed NCT02566265 - Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients Phase 2
Completed NCT00422656 - Perifosine in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia Phase 2
Completed NCT00165295 - Sildenafil Citrate in Waldenstrom's Macroglobulinemia Phase 2
Completed NCT00150462 - Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies Phase 1
Terminated NCT00142168 - CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia Phase 2
Suspended NCT02439138 - Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia Phase 2
Completed NCT01470196 - Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia Phase 2
Completed NCT00250926 - Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia Phase 2
Terminated NCT03225716 - A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia Phase 1
Terminated NCT01744912 - Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies Phase 1
Completed NCT02363439 - Extension Study of IMO-8400 in Patients With Waldenström's Macroglobulinemia Who Completed Study 8400-401 Phase 1/Phase 2
Completed NCT00976248 - Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia Phase 2
Terminated NCT00575965 - Simvastatin in Waldenstrom's Macroglobulinemia Phase 2
Completed NCT00919139 - S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS. N/A
Completed NCT01614821 - Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia Phase 2
Active, not recruiting NCT01078974 - Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia Phase 1
Completed NCT00481871 - Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies Phase 1/Phase 2
Completed NCT00142116 - Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia Phase 2
Completed NCT02092909 - Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia Phase 1/Phase 2
Completed NCT00807677 - A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies Phase 1